Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Synthesizing images of tau pathology from cross-modal neuroimaging using deep learning
Lee, Jeyeon , Burkett, Brian J. , Min, Hoon‐Ki , Dicks, Ellen , Corriveau‐Lecavalier, Nick , Mester, Carly , Wiste, Heather J. , Murray, Melissa E. , Nguyen, Aivi T. , Reichard, Ross R., Graff‐Radford, Jonathan , Barnard, Leland R , Gunter, Jeffrey L. , Kantarci, Kejal , Lowe, Val J. , Petersen, Ronald C. , Jack, Clifford R. , Corriveau-Lecavalier, Nick , Mester, Carly T, Lundt, Emily S. , Murray, Melissa E , Botha, Hugo , Graff-Radford, Jonathan , Schwarz, Christopher G , Kantarci, Kejal , Knopman, David S. , Boeve, Brad , Jack, Clifford R , Jones, David T , Min, Hoon-Ki Paul , Nguyen, Aivi T , Burkett, Brian , Senjem, Matthew L. , Botha, Hugo , Schwarz, Christopher G. , Knopman, David S. , Boeve, Bradley F. , Jones, David T.

Mayo Clinic

Brain | October 7, 2023 | Volume: 147 | Issue: 3 | Pages: 980-995

10.1093/brain/awad346 | PMID 37804318 Get It

Abstract Given the prevalence of dementia and the development of pathology-specific disease-modifying therapies, high-value biomarker strategies to inform medical decision-making are critical. In vivo tau-PET is an ideal target as a biomarker for Alzheimer’s disease diagnosis and treatment outcome measure. However, tau-PET is not currently widely accessible to patients compared to other neuroimaging methods. In this study, we present a convolutional neural network (CNN) model that imputes tau-PET images from more widely available cross-modality imaging inputs. Participants (n = 1192) with brain T1-weighted MRI (T1w), fluorodeoxyglucose (FDG)-PET, amyloid-PET and tau-PET were included. We found that a CNN model can impute tau-PET images with high accuracy, the highest being for the FDG-based model followed by amyloid-PET and T1w. In testing implications of artificial intelligence-imputed tau-PET, only the FDG-based model showed a significant improvement of performance in classifying tau positivity and diagnostic groups compared to the original input data, suggesting that application of the model could enhance the utility of the metabolic images. The interpretability experiment revealed that the FDG- and T1w-based models utilized the non-local input from physically remote regions of interest to estimate the tau-PET, but this was not the case for the Pittsburgh compound B-based model. This implies that the model can learn the distinct biological relationship between FDG-PET, T1w and tau-PET from the relationship between amyloid-PET and tau-PET. Our study suggests that extending neuroimaging’s use with artificial intelligence to predict protein specific pathologies has great potential to inform emerging care models.
Response to comment on “Gender bias in postgraduate year one pharmacy letters of recommendation”
Drury, Anna Sahlstrom , Leung, Jonathan G. , Nei, Scott D. , Moon, Jean , Turpin, Brittany Bissell, Leung, Jonathan G , Witenko, Corey J. , Turpin, Brittany D. Bissell

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | October 6, 2023 | Volume: 6 | Issue: 10 | Pages: 1161-1162

10.1002/jac5.1874 Get It

Consensus statement: An evidence‐based review of exercise, rehabilitation, rest, and return to activity protocols for the treatment of concussion and mild traumatic brain injury
Luigi, Arthur Jason De , Bell, Kathleen , Bramhall, Joe P., Choe, Meeryo , Dec, Katherine L., Halstead, Mark, Herring, Stanley A., Matuszak, Jason, Raksin, P B , Swanson, Jennifer, Millett, Carolyn, De Luigi, Arthur J , Bell, Kathleen , Finnoff, Jonathan T. , Halstead, Mark, Swanson, Jennifer, Millett, Carolyn

Mayo Clinic

PM&R | October 5, 2023 | Volume: 15 | Issue: 12 | Pages: 1605-1642

10.1002/pmrj.13070 | PMID 37794736 Get It

Abstract Background Early diagnosis and appropriate management of concussion/mild traumatic brain injury (mTBI) is critical for preventing poor outcomes and minimizing health care burden. Current clinical guidelines for concussion management focus mostly on diagnosis and return to cognitive and physical activity but provide limited guidance on the use of specific therapeutic interventions. Objective To systematically review the available evidence on therapeutic interventions for concussion/mTBI and develop an evidence‐based consensus statement on the use of these interventions in clinical practice. Literature Survey A systematic literature search was performed first in 2018 and 2019, and again in 2022, to identify relevant original research on these interventions. A total of 6303 articles were retrieved through the systematic literature search and screened for inclusion. Eighty articles met inclusion criteria and were included in this review and consensus process. Methodology A multispecialty panel was convened to explore management of concussion/mTBI. Interventions evaluated included rest, exercise, rehabilitation, and return to activity (RTA) protocols. Studies were assessed for relevance and methodologic quality and were voted upon to develop an evidence‐based consensus statement on the therapeutic appropriateness of these interventions for concussion/mTBI. A meta‐analysis was not performed. Synthesis There was sufficient evidence to recommend exercise as an appropriate therapy for adolescents with acute concussion/mTBI. In other age groups and for other therapeutic modalities, although some studies demonstrated benefits for some of the interventions, mixed results and study limitations prevented the panel from drawing firm conclusions on the efficacy of those interventions. The panel found evidence of detrimental effects from strict rest and high‐intensity physical activity. Conclusions The panel recommended exercise as an appropriate therapy for acute concussion in adolescents. The evidence on other therapeutic interventions for concussion/mTBI remains limited to small randomized controlled trials and observational studies of moderate to low quality. The panel found no strong evidence to support or recommend against the other evaluated interventions but found most interventions to be safe when used judiciously and in consideration of individual patient needs. High‐quality randomized studies with sufficient power are needed to evaluate the effects of rest, rehabilitation, and RTA protocols for the management of concussion/mTBI.
Comparison of health care costs and resource utilization for commonly used proteasome inhibitor–immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States
Sanchez, Larysa , Cheng, Mu, Cherepanov, Dasha , DerSarkissian, Maral , Stull, Dawn Marie, Dabora, Jonathan, Young, Melanie , Noga, Stephen J. , Pi, Selina , Banatwala, Azeem , Duh, Mei Sheng , Chari, Ajai , Chari, Ajai , Huang, Fei, Zhang, Melody , Ailawadhi, Sikander

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | September 30, 2023 | Volume: 29 | Issue: 11 | Pages: 1205-1218

10.18553/jmcp.2023.23031 | PMID 37776124 Get It

Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
Rivero, Jaydira Del , Perez, Kimberly , Kennedy, Erin B. , Mittra, Erik , Vijayvergia, Namrata , Arshad, Junaid , Basu, Sandip , Chauhan, Aman , Dasari, Arvind , Bellizzi, Andrew M. , Gangi, Alexandra , Grady, Erin , Ivanidze, Jana , Lewis, Mark A. , Mailman, Josh , Raj, Nitya , White, Sarah B. , Chan, Jennifer A. , Kunz, Pamela L. , Singh, Simron , Bergsland, Emily K. , Del Rivero, Jaydira , Dasari, Arvind N , Howe, James R , Raj, Nitya , Soares, Heloisa P , Soulen, Michael C , Kunz, Pamela L , Singh, Simron , Halfdanarson, Thorvardur R , Strosberg, Jonathan R , Bergsland, Emily K , Chauhan, Aman , Bellizzi, Andrew M , Vijayvergia, Namrata , Arshad, Junaid , Howe, James R. , Soares, Heloisa P. , Hálfdánarson, Þorvarður R. , Strosberg, Jonathan

Mayo Clinic

Journal of Clinical Oncology | September 29, 2023 | Volume: 41 | Issue: 32 | Pages: 5049-5067

10.1200/jco.23.01529 | PMID 37774329 Get It

PURPOSE To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). METHODS ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS Eight randomized controlled trials met the inclusion criteria for the systematic review. RECOMMENDATIONS Somatostatin analogs (SSAs) are recommended as first-line systemic therapy for most patients with G1-grade 2 (G2) metastatic well-differentiated GI-NETs. Observation is an option for patients with low-volume or slow-growing disease without symptoms. After progression on SSAs, peptide receptor radionuclide therapy (PRRT) is recommended as systematic therapy for patients with somatostatin receptor (SSTR)–positive tumors. Everolimus is an alternative second-line therapy, particularly in nonfunctioning NETs and patients with SSTR-negative tumors. SSAs are standard first-line therapy for SSTR-positive pancreatic (pan)NETs. Rarely, observation may be appropriate for asymptomatic patients until progression. Second-line systemic options for panNETs include PRRT (for SSTR-positive tumors), cytotoxic chemotherapy, everolimus, or sunitinib. For SSTR-negative tumors, first-line therapy options are chemotherapy, everolimus, or sunitinib. There are insufficient data to recommend particular sequencing of therapies. Patients with G1-G2 high-volume disease, relatively high Ki-67 index, and/or symptoms related to tumor growth may benefit from early cytotoxic chemotherapy. For G3 GEP-NETs, systemic options for G1-G2 may be considered, although cytotoxic chemotherapy is likely the most effective option for patients with tumor-related symptoms, and SSAs are relatively ineffective. Qualifying statements are provided to assist with treatment choice. Multidisciplinary team management is recommended, along with shared decision making with patients, incorporating their values and preferences, potential benefits and harms, and other characteristics and circumstances, such as comorbidities, performance status, geographic location, and access to care. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease
Lee, Yoo Jin , Li, Dalin , Debbas, Philip , Hampton, Melissa, Ebinger, Joseph E. , Chiorean, Michael , Lum, Donald , Damas, Oriana M. , Melmed, Gil , Group, CORALE-IBD Study, Banty, Andrea, Feldman, Edward J., Ha, Christina , Lee, Susie, Rabizadeh, Shervin , Stein, Theodore , Solomon, Theodore, Syal, Gaurav , Targan, Stephan R. , Vasiliauskas, Eric, Ziring, David , Bonthala, Niru, Botwin, Gregory S, Khanishian, Elizabeth, Pozdnyakova, Valeriya , Gu, Phillip , White, Shane , Zamudio, Cindy, Gonzalez, Daniel , Parry, Alyssa, Hanna, Mary , Chan, Justin, Ebinger, Joe , Wu, Min , Hoang, Amy, Wynter, Timothy , Sun, Nancy , Figueiredo, Jane C. , Merchant, Akil , Merin, Noah , Appel, Keren , Boland, Brigid S. , Charabaty, Aline , Cohen, Erica , Flynn, Ann D. , Valentine, John F. , Ehrlich, Adam C., Fudman, David , Horizon, Arash, Karayev, Dmitry, Kretzmann, Benjamin, Hou, Jason K. , Hwang, Caroline, Lazarev, Mark , Fausel, Rebecca, Reddy, Swapna , McConnell, Ryan , Mattar, Mark , Metwally, Mark, Ostrov, Arthur, Parekh, Nimisha, Raffals, Laura H., Sheibani, Sarah , Younes, Ziad , Braun, Jonathan , Melmed, Gil Y , Mujukian, Angela , Mengesha, Emebet , Cheng, Susan , McGovern, Dermot , Group, CORALE-IBD Study, Botwin, Gregory J., White, Shane, Joung, Sandy , Hoang, Amy, Reckamp, Karen L. , Kumar, Rashmi , Rubin, David T. , Siegel, Corey A , Wolf, Douglas C.

Mayo Clinic

Inflammatory Bowel Diseases | September 29, 2023 | Volume: 30 | Issue: 8 | Pages: 1430-1434

10.1093/ibd/izad198 | PMID 37773982 Get It

Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1
Gross, Andrea M. , Watts, Nelson B. , Fisher, Michael J. , Klesse, Laura J. , Lessing, Andrés J , McManus, M. L. , Oberlander, Beverly, Rios, Jonathan J. , Sarnoff, Herb , Simpson, Brittany , Ullrich, Nicole J. , Stevenson, David A. , Fisher, Michael J , Klesse, Laura J , Lessing, Andrés J , McManus, Miranda L , Sarnoff, Herb , Simpson, Brittany N , Gross, Andrea M , Plotkin, Scott R. , Larson, A. Noelle

Mayo Clinic

Clinical Trials | September 29, 2023 | Volume: 21 | Issue: 1 | Pages: 29-39

10.1177/17407745231201338 | PMID 37772407 Get It

Neurofibromatosis type 1 is a genetic syndrome characterized by a wide variety of tumor and non-tumor manifestations. Bone-related issues, such as scoliosis, tibial dysplasia, and low bone mineral density, are a significant source of morbidity for this population with limited treatment options. Some of the challenges to developing such treatments include the lack of consensus regarding the optimal methods to assess bone health in neurofibromatosis type 1 and limited data regarding the natural history of these manifestations. In this review, the Functional Committee of the Response Evaluation in Neurofibromatosis and Schwannomatosis International Collaboration: (1) presents the available techniques for measuring overall bone health and metabolism in persons with neurofibromatosis type 1, (2) reviews data for use of each of these measures in the neurofibromatosis type 1 population, and (3) describes the strengths and limitations for each method as they might be used in clinical trials targeting neurofibromatosis type 1 bone manifestations. The Response Evaluation in Neurofibromatosis and Schwannomatosis International Collaboration supports the development of a prospective, longitudinal natural history study focusing on the bone-related manifestations and relevant biomarkers of neurofibromatosis type 1. In addition, we suggest that the neurofibromatosis type 1 research community consider adding the less burdensome measurements of bone health as exploratory endpoints in ongoing or planned clinical trials for other neurofibromatosis type 1 manifestations to expand knowledge in the field.
No Increased Mercury Release from Dental Restorations at 1.5T, 3T, or 7T MRI
Burkett, Brian J. , Rasmussen, Chad M. , Fillmore, W. Jonathan , McDonald, Robert J. , Fagan, Andrew , Erdahl, Sarah A , Eckdahl, Steven J., Welker, Kirk M. , Fagan, Andrew J , Burkett, Brian , McDonald, Jennifer S.

Mayo Clinic

Magnetic Resonance in Medicine | September 27, 2023 | Volume: 91 | Issue: 2 | Pages: 660-669

10.1002/mrm.29872 | PMID 37755142 Get It

AbstractPurposeDental amalgam contains mercury and is commonly used in dental restorations. The impact of MRI on mercury excretion from dental amalgam is not well understood across clinical field strengths, especially 7T. We investigated the effects of MRI exposure on mercury excretion using fresh, lab‐created dental amalgam restorations and in extracted teeth with old, pre‐existing restorations.MethodsDonated, unfilled human teeth (n = 120) were restored with amalgam before being stored in saline, artificial saliva, or a dry box prior to MRI scanning. The teeth were placed in individual tubes of fresh artificial saliva and scanned at 1.5T, 3T, or 7T or left unscanned as controls. Mercury concentrations were measured 24–30 h later. Donated teeth with pre‐existing restorations (n = 40) were stored in artificial saliva, scanned at 7T or left unscanned as controls, and mercury concentration tested.ResultsFor teeth extracted and restored in a laboratory, no significant difference was found (F = 2.42, P = 0.072) between mean mercury concentrations of unscanned teeth (13.72 μg/L) and teeth scanned at 1.5T (10.88 μg/L), 3T (12.65 μg/L), or 7T (8.88 μg/L). For teeth extracted with previously placed restorations, no significant difference (P = 0.288) was found between unscanned controls (4.28 μg/L) and teeth scanned at 7T (6.63 μg/L).ConclusionMRI of dental amalgam does not significantly increase mercury excretion at 1.5T, 3T, or 7T compared to unscanned teeth. This holds true for controlled laboratory restorations as well as for those placed and lived with prior to extraction and scanning, demonstrating no added risk to the clinical patient or research subject.
Statement from the Asia Summit: Current state of arrhythmia care in Asia
Agbayani, Michael‐Joseph F., Choi, Jong‐Il , Dan, Van Buu , Hanafy, Dicky A, Hurwitz, Jodie L. , Kalman, Jonathan M. , Khan, Aamir Hameed H., Khmao, Pichmanil , Ngarmukos, Tachapong , Nguyen, Son Thai Binh, Nwe, Nwe, Soejima, Kyoko , Stiles, Martin K. , TSAO, HSUAN‐MING , Tseveendee, Saruul, Shimizu, Wataru , Kusumoto, Fred , Apiyasawat, Sirin , Chen, Ming-Long , Ching, Chi Keong , Hanafy, Dicky Armein , Johar, Sofian , Krahn, Andrew D. , Nwe, Nwe, Oh, Seil

Mayo Clinic

Journal of Arrhythmia | September 27, 2023 | Volume: 40 | Issue: 1 | Pages: 1-16

10.1002/joa3.12935 Get It

AbstractOn May 27, 2022, the Asia Pacific Heart Rhythm Society and the Heart Rhythm Society convened a meeting of leaders from different professional societies of healthcare providers committed to arrhythmia care from the Asia Pacific region. The overriding goals of the meeting were to discuss clinical and health policy issues that face each country for providing care for patients with electrophysiologic issues, share experiences and best practices, and discuss potential future solutions. Participants were asked to address a series of questions in preparation for the meeting. The format of the meeting was a series of individual country reports presented by the leaders from each of the professional societies followed by open discussion. The recorded presentations from the Asia Summit can be accessed at https://www.heartrhythm365.org/URL/asiasummit‐22. Three major themes arose from the discussion. First, the major clinical problems faced by different countries vary. Although atrial fibrillation is common throughout the region, the most important issues also include more general issues such as hypertension, rheumatic heart disease, tobacco abuse, and management of potentially life‐threatening problems such as sudden cardiac arrest or profound bradycardia. Second, there is significant variability in the access to advanced arrhythmia care throughout the region because of differences in workforce availability, resources, drug availability, and national health policies. Third, collaboration in the area already occurs between individual countries, but no systematic regional method for working together is present.
Incidence Of Illnesses Among Team Usa Athletes Competing In The Beijing 2022 Winter Paralympic Games
Cali, Malia G. , Clark, Stephanie C., Hasley, Ike B., Larson, Emily G., Noble-Taylor, Kayle E., Finnoff, Jonathan T. , Clark, Stephanie C., McPherson, April L. , Robinson, David M. , Adams, William M.

Mayo Clinic

Medicine & Science in Sports & Exercise | September 26, 2023 | Volume: 55 | Issue: 9S | Pages: 81-82

10.1249/01.mss.0000980448.16663.ff Get It